Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Flucelvax
Vaccines
Seqirus to spend $140M in N.C. flu vaccine plant expansion
Seqirus plans to add cell-based and adjuvanted flu vaccine capacity in a $140 million expansion to its plant in Holly Springs, North Carolina.
Eric Sagonowsky
Nov 19, 2018 5:00pm
Seqirus' cell-based Flucelvax nears first-ever EU approval
Oct 23, 2018 10:30am
Sanofi teams with ALA on flu-shot message to U.S. seniors
Oct 15, 2018 3:02pm
Cell-derived flu strain provides a better match than eggs: study
Oct 10, 2018 8:47am
GSK, Seqirus begin shipping flu vaccines for the 2018-19 season
Aug 14, 2018 11:49am
Cell-based flu shots offer slight advantage for seniors: report
Jun 27, 2018 9:10am
